84 results on '"Janning M"'
Search Results
2. Correction: Role of growth arrest-specific gene 6-mer axis in multiple myeloma
- Author
-
Waizenegger, J. S., Ben-Batalla, I., Weinhold, N., Meissner, T., Wroblewski, M., Janning, M., Riecken, K., Binder, M., Atanackovic, D., Taipaleenmaeki, H., Schewe, D., Sawall, S., Gensch, V., Cubas-Cordova, M., Seckinger, A., Fiedler, W., Hesse, E., Kröger, N., Fehse, B., Hose, D., Klein, B., Raab, M. S., Pantel, K., Bokemeyer, C., and Loges, S.
- Published
- 2020
- Full Text
- View/download PDF
3. P548: BEMCENTINIB COMBINED WITH LOW-DOSE CYTARABINE IS EFFICACIOUS AND WELL TOLERATED IN RELAPSED AML PATIENTS UNFIT FOR INTENSIVE CHEMOTHERAPY. UPDATES FROM THE ONGOING PHASE II TRIAL (NCT02488408)
- Author
-
Loges, S., primary, Heuser, M., additional, Chromik, J., additional, Sutamtewagul, G., additional, Kapp-Schwoerer, S., additional, Crugnola, M., additional, Di Renzo, N., additional, Lemoli, R., additional, Mattei, D., additional, Ben-Batalla, I., additional, Waizenegger, J., additional, Rieckmann, L.-M., additional, Janning, M., additional, Imbusch, C. D., additional, Beumer, N., additional, Micklem, D., additional, Gorcea-Carson, C., additional, Lawson, G., additional, Nautiyal, J., additional, Deharo, S., additional, Fiedler, W., additional, Alvarado-Valero, Y., additional, and Gjertsen, B., additional
- Published
- 2022
- Full Text
- View/download PDF
4. Treatment outcome of atypical EGFR mutations in the German National Network Genomic Medicine Lung Cancer (nNGM)
- Author
-
Janning, M., primary, Süptitz, J., additional, Albers-Leischner, C., additional, Delpy, P., additional, Tufman, A., additional, Velthaus-Rusik, J.-L., additional, Reck, M., additional, Jung, A., additional, Kauffmann-Guerrero, D., additional, Bonzheim, I., additional, Brändlein, S., additional, Hummel, H.-D., additional, Wiesweg, M., additional, Schildhaus, H.-U., additional, Stratmann, J.A., additional, Sebastian, M., additional, Alt, J., additional, Buth, J., additional, Esposito, I., additional, Berger, J., additional, Tögel, L., additional, Saalfeld, F.C., additional, Wermke, M., additional, Merkelbach-Bruse, S., additional, Hillmer, A.M., additional, Klauschen, F., additional, Bokemeyer, C., additional, Buettner, R., additional, Wolf, J., additional, Loges, S., additional, Simon, Ronald, additional, Sauter, Guido, additional, Volk, Alexander, additional, Neumann, Jens, additional, Klauschen, Frederick, additional, Weichert, Wilko, additional, Kalhori, Naser, additional, Lüthen, Reinhard, additional, Stöhr, Robert, additional, Schubart, Chistoph, additional, Wacker, Heidemarie, additional, Fuchs, Florian, additional, Hartmann, Nils, additional, Graf, Stefanie, additional, Brandts, Christian, additional, Wild, Peter, additional, Demes, Melanie, additional, Reis, Henning, additional, and Rohde, Gernot, additional
- Published
- 2022
- Full Text
- View/download PDF
5. Treatment outcome of atypical EGFR mutations in the German National Network Genomic Medicine Lung Cancer (nNuM)
- Author
-
Janning, M., Sueptitz, J., Albers-Leischner, C., Delpy, P., Tufman, A., Velthaus-Rusik, J-L, Reck, M., Jung, A., Kauffmann-Guerrero, D., Bonzheim, I, Braendlein, S., Hummel, H-D, Wiesweg, M., Schildhaus, H-U, Stratmann, J. A., Sebastian, M., Alt, J., Buth, J., Esposito, I, Berger, J., Toegel, L., Saalfeld, F. C., Wermke, M., Merkelbach-Bruse, S., Hillmer, A. M., Klauschen, F., Bokemeyer, C., Buettner, R., Wolf, J., Loges, S., Janning, M., Sueptitz, J., Albers-Leischner, C., Delpy, P., Tufman, A., Velthaus-Rusik, J-L, Reck, M., Jung, A., Kauffmann-Guerrero, D., Bonzheim, I, Braendlein, S., Hummel, H-D, Wiesweg, M., Schildhaus, H-U, Stratmann, J. A., Sebastian, M., Alt, J., Buth, J., Esposito, I, Berger, J., Toegel, L., Saalfeld, F. C., Wermke, M., Merkelbach-Bruse, S., Hillmer, A. M., Klauschen, F., Bokemeyer, C., Buettner, R., Wolf, J., and Loges, S.
- Abstract
Background: Atypical EGFR mutations occur in 10%-30% of non-small-cell lung cancer (NSCLC) patients with EGFR mutations and their sensitivity to classical epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKI) is highly heterogeneous. Patients harboring one group of uncommon, recurrent EGFR mutations (G719X, 57681, L861Q) respond to EGFR-TKI. Exon 20 insertions are mostly insensitive to EGFR-TKI but display sensitivity to exon 20 inhibitors. Clinical outcome data of patients with very rare point and compound mutations upon systemic treatments are still sparse to date. Patients and methods: In this retrospective, multicenter study of the national Network Genomic Medicine (nNGM) in Germany, 856 NSCLC cases with atypical EGFR mutations including co-occurring mutations were reported from 12 centers. Clinical follow-up data after treatment with different EGFR-TKIs, chemotherapy and immune checkpoint inhibitors were available from 260 patients. Response to treatment was analyzed in three major groups: (i) uncommon mutations (G719X, 57681, L861Q and combinations), (ii) exon 20 insertions and (iii) very rare EGFR mutations (very rare single point mutations, compound mutations, exon 18 deletions, exon 19 insertions). Results: Our study comprises the largest thus far reported real-world cohort of very rare EGFR single point and compound mutations treated with different systemic treatments. We validated higher efficacy of EGFR-TKI in comparison to chemotherapy in group 1 (uncommon), while most exon 20 insertions (group 2) were not EGFR-TKI responsive. In addition, we found TKI sensitivity of very rare point mutations (group 3) and of complex EGFR mutations containing exon 19 deletions or L858R mutations independent of the combination partner. Notably, treatment responses in group 3 (very rare) were highly heterogeneous. Co-occurring TP53 mutations exerted a non-significant trend for a detrimental effect on outcome in EGFR-TKI-treated patients in groups 2 and
- Published
- 2022
6. Role of Growth arrest-specific gene 6-Mer axis in multiple myeloma
- Author
-
Waizenegger, J S, Ben-Batalla, I, Weinhold, N, Meissner, T, Wroblewski, M, Janning, M, Riecken, K, Binder, M, Atanackovic, D, Taipaleenmaeki, H, Schewe, D, Sawall, S, Gensch, V, Cubas-Cordova, M, Seckinger, A, Fiedler, W, Hesse, E, Kröger, N, Fehse, B, Hose, D, Klein, B, Raab, M S, Pantel, K, Bokemeyer, C, and Loges, S
- Published
- 2015
- Full Text
- View/download PDF
7. A novel microfluidic platform for size and deformability based separation and the subsequent molecular characterization of viable circulating tumor cells
- Author
-
Hvichia, G. E., Parveen, Z., Wagner, C., Janning, M., Quidde, J., Stein, A., Müller, V., Loges, S., Neves, R. P.L., Stoecklein, N. H., Wikman, H., Riethdorf, S., Pantel, K., and Gorges, T. M.
- Published
- 2016
- Full Text
- View/download PDF
8. Response to treatment of uncommon EGFR mutations : a retrospective analysis from the German National Network Genomic Medicine Lung Cancer (nNGM)
- Author
-
Janning, M., Süptitz, J., Wiesweg, Marcel, Schildhaus, Hans-Ulrich, and Loges, S.
- Subjects
Medizin - Abstract
Weitere Verfasser:innen aus Einrichtungen außerhalb der Universität Duisburg-Essen sind nicht aufgeführt
- Published
- 2021
9. 1431P The nNGM Preclinical Platform: Preclinical research to generate evidence for patients with non-small cell lung cancer harboring variants of unknown significance
- Author
-
Ziegler, M., Albers-Leischner, C., Salgueiro, L., Khoury, N., Sharapova, Y., Saalfeld, F.C., Wenzel, C., Scharpenseel, H., Schmidt, C., Naveja-Romero, J., Meemboor, S., Hillmer, A., Nogova, L., Wermke, M., Wolf, J., Diederichs, S., Brummer, T., Büttner, R., Janning, M., and Loges, S.
- Published
- 2023
- Full Text
- View/download PDF
10. Frequency–Redshift Relation of the Cosmic Microwave Background
- Author
-
Ralf Hofmann and Janning Meinert
- Subjects
thermal ground state ,thermal Sunyaev-Zel’dovich effect ,microwave absorber clouds ,cosmic microwave background ,Astronomy ,QB1-991 - Abstract
We point out that a modified temperature–redshift relation (T-z relation) of the cosmic microwave background (CMB) cannot be deduced by any observational method that appeals to an a priori thermalisation to the CMB temperature T of the excited states in a probe environment of independently determined redshift z. For example, this applies to quasar-light absorption by a damped Lyman-alpha system due to atomic as well as ionic fine-splitting transitions or molecular rotational bands. Similarly, the thermal Sunyaev-Zel’dovich (thSZ) effect cannot be used to extract the CMB’s T-z relation. This is because the relative line strengths between ground and excited states in the former and the CMB spectral distortion in the latter case both depend, apart from environment-specific normalisations, solely on the dimensionless spectral variable x=hνkBT. Since the literature on extractions of the CMB’s T-z relation always assumes (i) ν(z)=(1+z)ν(z=0), where ν(z=0) is the observed frequency in the heliocentric rest frame, the finding (ii) T(z)=(1+z)T(z=0) just confirms the expected blackbody nature of the interacting CMB at z>0. In contrast to the emission of isolated, directed radiation, whose frequency–redshift relation (ν-z relation) is subject to (i), a non-conventional ν-z relation ν(z)=f(z)ν(z=0) of pure, isotropic blackbody radiation, subject to adiabatically slow cosmic expansion, necessarily has to follow that of the T-z relation T(z)=f(z)T(z=0) and vice versa. In general, the function f(z) is determined by the energy conservation of the CMB fluid in a Friedmann–Lemaitre–Robertson–Walker universe. If the pure CMB is subject to an SU(2) rather than a U(1) gauge principle, then f(z)=1/41/3(1+z) for z≫1, and f(z) is non-linear for z∼1.
- Published
- 2023
- Full Text
- View/download PDF
11. 153P Real-world study of NSCLC with EGFR exon 20 insertions
- Author
-
Christopoulos, P., primary, Grohé, C., additional, Griesinger, F., additional, Falkenstern-Ge, R.F., additional, Krisam, J., additional, Brückner, L., additional, Wermke, M., additional, Misch, D., additional, Hackanson, B., additional, Faehling, M., additional, Tufman, A., additional, Janning, M., additional, Schulz, C., additional, Reck, M., additional, Hong, J-L., additional, Lin, H.M., additional, Stenzinger, A., additional, and Thomas, M., additional
- Published
- 2021
- Full Text
- View/download PDF
12. Multicenter Evaluation of Independent High-Throughput and RT-qPCR Technologies for the Development of Analytical Workflows for Circulating miRNA Analysis.
- Author
-
Babayan, A, Neumann, MHD, Herdean, A, Shaffer, JM, Janning, M, Kobus, F, Loges, S, Di Pasquale, F, Kubista, M, Schlumpberger, M, Lampignano, R, Krahn, T, Schlange, T, Sprenger-Haussels, M, Pantel, K, Kloten, V, Babayan, A, Neumann, MHD, Herdean, A, Shaffer, JM, Janning, M, Kobus, F, Loges, S, Di Pasquale, F, Kubista, M, Schlumpberger, M, Lampignano, R, Krahn, T, Schlange, T, Sprenger-Haussels, M, Pantel, K, and Kloten, V
- Abstract
BACKGROUND:Among emerging circulating biomarkers, miRNA has the potential to detect lung cancer and follow the course of the disease. However, miRNA analysis deserves further standardization before implementation into clinical trials or practice. Here, we performed international ring experiments to explore (pre)-analytical factors relevant to the outcome of miRNA blood tests in the context of the EU network CANCER-ID. METHODS:Cell-free (cfmiRNA) and extracellular vesicle-derived miRNA (EVmiRNA) were extracted using the miRNeasy Serum/Plasma Advanced, and the ExoRNeasy Maxi kit, respectively, in a plasma cohort of 27 NSCLC patients and 20 healthy individuals. Extracted miRNA was investigated using small RNA sequencing and hybridization platforms. Validation of the identified miRNA candidates was performed using quantitative PCR. RESULTS:We demonstrate the highest read counts in healthy individuals and NSCLC patients using QIAseq. Moreover, QIAseq showed 15.9% and 162.9% more cfmiRNA and EVmiRNA miRNA counts, respectively, in NSCLC patients compared to healthy control samples. However, a systematic comparison of selected miRNAs revealed little agreement between high-throughput platforms, thus some miRNAs are detected with one technology, but not with the other. Adding to this, 35% (9 of 26) of selected miRNAs in the cfmiRNA and 42% (11 of 26) in the EVmiRNA fraction were differentially expressed by at least one qPCR platform; about half of the miRNAs (54%) were concordant for both platforms. CONCLUSIONS:Changing of (pre)-analytical methods of miRNA analysis has a significant impact on blood test results and is therefore a major confounding factor. In addition, to confirm miRNA biomarker candidates screening studies should be followed by targeted validation using an independent platform or technology.
- Published
- 2020
13. Risk stratification of EGFR+ lung cancer diagnosed with panel-based next-generation sequencing
- Author
-
Christopoulos, P., primary, Kirchner, M., additional, Roeper, J., additional, Saalfeld, F., additional, Janning, M., additional, Bozorgmehr, F., additional, Magios, N., additional, Kazdal, D., additional, Volckmar, A.L., additional, Brückner, L.M., additional, Bochtler, T., additional, Kriegsmann, M., additional, Endris, V., additional, Penzel, R., additional, Kriegsmann, K., additional, Eichhorn, M., additional, Herth, F.J.F., additional, Heussel, C.P., additional, El Shafie, R.A., additional, Schneider, M.A., additional, Muley, T., additional, Meister, M., additional, Faehling, M., additional, Fischer, J.R., additional, Heukamp, L., additional, Schirmacher, P., additional, Bischoff, H., additional, Wermke, M., additional, Loges, S., additional, Griesinger, F., additional, Stenzinger, A., additional, and Thomas, M., additional
- Published
- 2020
- Full Text
- View/download PDF
14. S880 A PHASE II STUDY OF SELINEXOR PLUS CYTARABINE AND IDARUBICIN IN PATIENTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA (AML)
- Author
-
Fiedler, W., primary, Chromik, J., additional, Amberg, S., additional, Kebenko, M., additional, Thol, F., additional, Schlipfenbacher, V., additional, Wilke, A. C., additional, Modemann, F., additional, Janning, M., additional, Serve, H., additional, Ganser, A., additional, Bokemeyer, C., additional, Theile, S., additional, Deppermann, U., additional, Kranich, A., additional, and Heuser, M., additional
- Published
- 2019
- Full Text
- View/download PDF
15. The DKTK EXLIQUID consortium – exploiting liquid biopsies to advance cancer precision medicine for molecular tumor board patients
- Author
-
Mack Matthias, Broche Julian, George Stephen, Hajjari Zahra, Janke Florian, Ranganathan Lavanya, Ashouri Mohammadreza, Bleul Sabine, Desuki Alexander, Engels Cecilia, Fliedner Stephanie M.J., Hartmann Nils, Hummel Michael, Janning Melanie, Kiel Alexander, Köhler Thomas, Koschade Sebastian, Lablans Martin, Lambarki Mohamed, Loges Sonja, Lueong Smiths, Meyer Sandra, Ossowski Stephan, Scherer Florian, Schroeder Christopher, Skowronek Patrick, Thiede Christian, Uhl Barbara, Vehreschild Jörg Janne, von Bubnoff Nikolas, Wagner Sebastian, Werner Tamara V., Westphalen C. Benedikt, Fresser Patrizia, Sültmann Holger, Tinhofer Ingeborg, and Winter Christof
- Subjects
liquid profiling ,molecular profiling ,precision oncology ,Medical technology ,R855-855.5 - Abstract
Testing for genetic alterations in tumor tissue allows clinicians to identify patients who most likely will benefit from molecular targeted treatment. EXLIQUID – exploiting liquid biopsies to advance cancer precision medicine – investigates the potential of additional non-invasive tools for guiding therapy decisions and monitoring of advanced cancer patients. The term “liquid biopsy” (LB) refers to non-invasive analysis of tumor-derived circulating material such as cell-free DNA in blood samples from cancer patients. Although recent technological advances allow sensitive and specific detection of LB biomarkers, only few LB assays have entered clinical routine to date. EXLIQUID is a German Cancer Consortium (DKTK)-wide joint funding project that aims at establishing LBs as a minimally-invasive tool to analyze molecular changes in circulating tumor DNA (ctDNA). Here, we present the structure, clinical aim, and methodical approach of the new DKTK EXLIQUID consortium. Within EXLIQUID, we will set up a multicenter repository of high-quality LB samples from patients participating in DKTK MASTER and local molecular tumor boards, which use molecular profiles of tumor tissues to guide targeted therapies. We will develop LB assays for monitoring of therapy efficacy by the analysis of tumor mutant variants and tumor-specific DNA methylation patterns in ctDNA from these patients. By bringing together LB experts from all DKTK partner sites and exploiting the diversity of their particular expertise, complementary skills and technologies, the EXLIQUID consortium addresses the challenges of translating LBs into the clinic. The DKTK structure provides EXLIQUID a unique position for the identification of liquid biomarkers even in less common tumor types, thereby extending the group of patients benefitting from non-invasive LB testing. Besides its scientific aims, EXLIQUID is building a valuable precision oncology cohort and LB platform which will be available for future collaborative research studies within the DKTK and beyond.
- Published
- 2022
- Full Text
- View/download PDF
16. Modified Temperature–Redshift Relation and Ultra-high-energy Cosmic Ray Propagation
- Author
-
Janning Meinert, Leonel Morejón, Alexander Sandrock, Björn Eichmann, Jonas Kreidelmeyer, and Karl-Heinz Kampert
- Subjects
Ultra-high-energy cosmic radiation ,Cosmological neutrinos ,Cosmology ,Astrophysics ,QB460-466 - Abstract
We reexamine the interactions of ultra-high-energy cosmic rays (UHECRs) with photons from the cosmic microwave background (CMB) under a changed, locally nonlinear temperature–redshift relation T ( z ). This changed temperature–redshift relation has recently been suggested by the postulate of subjecting thermalized and isotropic photon gases such as the CMB to an SU(2) rather than a U(1) gauge group. This modification of ΛCDM is called SU(2) _CMB , and some cosmological parameters obtained by SU(2) _CMB seem to be in better agreement with local measurements of the same quantities, in particular H _0 and S _8 . In this work, we apply the reduced CMB photon density under SU(2) _CMB to the propagation of UHECRs. This leads to a higher UHECR flux just below the ankle in the cosmic ray spectrum and slightly more cosmogenic neutrinos under otherwise equal conditions for emission and propagation. Most prominently, the proton flux is significantly increased below the ankle (5 × 10 ^18 eV) for hard injection spectra and without considering the effects of magnetic fields. The reduction in CMB photon density also favors a decreased cosmic ray source evolution than the best fit using ΛCDM. In consequence, it seems that SU(2) _CMB favors sources that evolve like the star formation rate, such as starburst galaxies and gamma-ray bursts, over active galactic nuclei as origins of UHECRs. We conclude that the question about the nature of primary sources of UHECRs is directly affected by the assumed temperature–redshift relation of the CMB.
- Published
- 2024
- Full Text
- View/download PDF
17. Mast cells decrease efficacy of anti-angiogenic therapy by secreting matrix-degrading granzyme B
- Author
-
Wroblewski, M., primary, Bauer, R., additional, Cubas Córdova, M., additional, Udonta, F., additional, Ben-Batalla, I., additional, Legler, K., additional, Hauser, C., additional, Egberts, J., additional, Janning, M., additional, Velthaus, J., additional, Schulze, C., additional, Pantel, K., additional, Bokemeyer, C., additional, and Loges, S., additional
- Published
- 2017
- Full Text
- View/download PDF
18. cN- und pN-Stadien bei primären Karzinomen der Glandula parotis
- Author
-
Schroeder, U, Krug, B, Semrau, R, Guntinas-Lichius, O, and Janning, M
- Subjects
ddc: 610 - Published
- 2008
19. Role of Growth arrest-specific gene 6-Mer axis in multiple myeloma
- Author
-
Waizenegger, J S, primary, Ben-Batalla, I, additional, Weinhold, N, additional, Meissner, T, additional, Wroblewski, M, additional, Janning, M, additional, Riecken, K, additional, Binder, M, additional, Atanackovic, D, additional, Taipaleenmaeki, H, additional, Schewe, D, additional, Sawall, S, additional, Gensch, V, additional, Cubas-Cordova, M, additional, Seckinger, A, additional, Fiedler, W, additional, Hesse, E, additional, Kröger, N, additional, Fehse, B, additional, Hose, D, additional, Klein, B, additional, Raab, M S, additional, Pantel, K, additional, Bokemeyer, C, additional, and Loges, S, additional
- Published
- 2014
- Full Text
- View/download PDF
20. Relevant bleeding diathesis due to acquired factor XIII deficiency
- Author
-
Janning, M., primary, Holstein, K., primary, Spath, B., primary, Schnabel, C., primary, Bannas, P., primary, Bokemeyer, C., primary, and Langer, F., additional
- Published
- 2013
- Full Text
- View/download PDF
21. Prognostischer Wert von Histologie und pTNM-Stadium bei primären Karzinomen der Glandula parotis
- Author
-
Schröder, U, primary, Janning, M, additional, Semrau, R, additional, and Guntinas-Lichius, O, additional
- Published
- 2005
- Full Text
- View/download PDF
22. Public spectacles of private spheres: an introduction to the special issue.
- Author
-
Janning M
- Abstract
This introduction to a special issue of the Journal of Family Issues, titled 'Spaces and Places of Family Life: Cultural and Popular Cultural Representations of Homes and Families,' calls attention to the intersections of conceptions of families and homes and to the cultural and popular cultural representations of both. Two themes make up the focus of the collection of articles contained in the special issue. First, the included articles explore the pieced-together media production of real and fictional families and homes. It is here we see the location of home and family as not quite real, not quite fictional, even if the families and homes represented are nonfictional (such as within the reality television genre). Second, this issue focuses on the relationship between media-produced images of homes and families and real everyday experiences, including whether real families use fictional and nonfictional media representations to situate and define themselves as families. The collection presented here begins to answer the question, What are the forms and locations in which popular culture and cultural definitions of homes and families shape each other? [ABSTRACT FROM AUTHOR]
- Published
- 2008
- Full Text
- View/download PDF
23. Axial Anomaly in Galaxies and the Dark Universe
- Author
-
Janning Meinert and Ralf Hofmann
- Subjects
galaxy rotation curves ,low surface brightness ,dark matter ,dark energy ,ultralight axion particles ,cores ,Elementary particle physics ,QC793-793.5 - Abstract
Motivated by the SU(2)CMB modification of the cosmological model ΛCDM, we consider isolated fuzzy-dark-matter lumps, made of ultralight axion particles whose masses arise due to distinct SU(2) Yang–Mills scales and the Planck mass MP. In contrast to SU(2)CMB, these Yang–Mills theories are in confining phases (zero temperature) throughout most of the Universe’s history and associate with the three lepton flavours of the Standard Model of particle physics. As the Universe expands, axionic fuzzy dark matter comprises a three-component fluid which undergoes certain depercolation transitions when dark energy (a global axion condensate) is converted into dark matter. We extract the lightest axion mass ma,e=0.675×10−23 eV from well motivated model fits to observed rotation curves in low-surface-brightness galaxies (SPARC catalogue). Since the virial mass of an isolated lump solely depends on MP and the associated Yang–Mills scale the properties of an e-lump predict those of μ- and τ-lumps. As a result, a typical e-lump virial mass ∼6.3×1010M⊙ suggests that massive compact objects in galactic centers such as Sagittarius A* in the Milky Way are (merged) μ- and τ-lumps. In addition, τ-lumps may constitute globular clusters. SU(2)CMB is always thermalised, and its axion condensate never has depercolated. If the axial anomaly indeed would link leptons with dark matter and the CMB with dark energy then this would demystify the dark Universe through a firmly established feature of particle physics.
- Published
- 2021
- Full Text
- View/download PDF
24. Put yourself in my work shoes: variations in work-related spousal support for professional married coworkers.
- Author
-
Janning M
- Abstract
Level and type of spousal shared work has been oversimplified in past research. This research proposes that being similar to a spouse, in the case of paidwork, differs depending on whether spouses shareworkplace, occupation, or both. And this level and type of similarity can influence the level and qualitative characteristics of work-related spousal support as an indicator of marital satisfaction. The results of this study are based on 52 individual semistructured interviews with each member of 26 professional married couples for whom work is shared in terms of occupation, workplace, both, or neither. The level and characteristics of spousal support vary to some extent by occupation pattern. Most strikingly, people who share both occupation and workplace feel that they work closely with their spouses and that working together has been beneficial to their marriages. However, the components of working together qualitatively vary by occupation category. [ABSTRACT FROM AUTHOR]
- Published
- 2006
- Full Text
- View/download PDF
25. Diagnostic leukapheresis reveals distinct phenotypes of NSCLC circulating tumor cells.
- Author
-
Rieckmann LM, Spohn M, Ruff L, Agorku D, Becker L, Borchers A, Krause J, O'Reilly R, Hille J, Velthaus-Rusik JL, Beumer N, Günther A, Willnow L, Imbusch CD, Iglauer P, Simon R, Franzenburg S, Winter H, Thomas M, Bokemeyer C, Gagliani N, Krebs CF, Sprick M, Hardt O, Riethdorf S, Trumpp A, Stoecklein NH, Peine S, Rosenstiel P, Pantel K, Loges S, and Janning M
- Subjects
- Humans, Single-Cell Analysis methods, Transcriptome, Epithelial-Mesenchymal Transition genetics, Gene Expression Profiling, Cell Line, Tumor, Neoplastic Cells, Circulating pathology, Neoplastic Cells, Circulating metabolism, Carcinoma, Non-Small-Cell Lung genetics, Carcinoma, Non-Small-Cell Lung diagnosis, Carcinoma, Non-Small-Cell Lung pathology, Leukapheresis, Lung Neoplasms genetics, Lung Neoplasms pathology, Lung Neoplasms diagnosis, Biomarkers, Tumor, Phenotype
- Abstract
Background: Circulating tumor cells (CTCs) hold immense promise for unraveling tumor heterogeneity and understanding treatment resistance. However, conventional methods, especially in cancers like non-small cell lung cancer (NSCLC), often yield low CTC numbers, hindering comprehensive analyses. This study addresses this limitation by employing diagnostic leukapheresis (DLA) to cancer patients, enabling the screening of larger blood volumes. To leverage DLA's full potential, this study introduces a novel approach for CTC enrichment from DLAs., Methods: DLA was applied to six advanced stage NSCLC patients. For an unbiased CTC enrichment, a two-step approach based on negative depletion of hematopoietic cells was used. Single-cell (sc) whole-transcriptome sequencing was performed, and CTCs were identified based on gene signatures and inferred copy number variations., Results: Remarkably, this innovative approach led to the identification of unprecedented 3,363 CTC transcriptomes. The extensive heterogeneity among CTCs was unveiled, highlighting distinct phenotypes related to the epithelial-mesenchymal transition (EMT) axis, stemness, immune responsiveness, and metabolism. Comparison with sc transcriptomes from primary NSCLC cells revealed that CTCs encapsulate the heterogeneity of their primary counterparts while maintaining unique CTC-specific phenotypes., Conclusions: In conclusion, this study pioneers a transformative method for enriching CTCs from DLA, resulting in a substantial increase in CTC numbers. This allowed the creation of the first-ever single-cell whole transcriptome in-depth characterization of the heterogeneity of over 3,300 NSCLC-CTCs. The findings not only confirm the diagnostic value of CTCs in monitoring tumor heterogeneity but also propose a CTC-specific signature that can be exploited for targeted CTC-directed therapies in the future. This comprehensive approach signifies a major leap forward, positioning CTCs as a key player in advancing our understanding of cancer dynamics and paving the way for tailored therapeutic interventions., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
26. Outcome of First-Line Treatment With Pembrolizumab According to KRAS/TP53 Mutational Status for Nonsquamous Programmed Death-Ligand 1-High (≥50%) NSCLC in the German National Network Genomic Medicine Lung Cancer.
- Author
-
Bischoff P, Reck M, Overbeck T, Christopoulos P, Rittmeyer A, Lüders H, Kollmeier J, Kulhavy J, Kemper M, Reinmuth N, Röper J, Janning M, Sommer L, Aguinarte L, Koch M, Wiesweg M, Wesseler C, Waller CF, Kauffmann-Guerrero D, Stenzinger A, Stephan-Falkenau S, Trautmann M, Lassmann S, Tiemann M, Klauschen F, Sebastian M, Griesinger F, Wolf J, Loges S, and Frost N
- Subjects
- Humans, Male, Female, Aged, Retrospective Studies, Middle Aged, Germany, Antineoplastic Agents, Immunological therapeutic use, Aged, 80 and over, B7-H1 Antigen metabolism, B7-H1 Antigen genetics, Adult, Treatment Outcome, Lung Neoplasms drug therapy, Lung Neoplasms genetics, Lung Neoplasms pathology, Carcinoma, Non-Small-Cell Lung drug therapy, Carcinoma, Non-Small-Cell Lung genetics, Carcinoma, Non-Small-Cell Lung pathology, Proto-Oncogene Proteins p21(ras) genetics, Antibodies, Monoclonal, Humanized therapeutic use, Tumor Suppressor Protein p53 genetics, Mutation
- Abstract
Introduction: Programmed death-ligand 1 expression currently represents the only validated predictive biomarker for immune checkpoint inhibition in metastatic NSCLC in the clinical routine, but it has limited value in distinguishing responses. Assessment of KRAS and TP53 mutations (mut) as surrogate for an immunosupportive tumor microenvironment (TME) might help to close this gap., Methods: A total of 696 consecutive patients with programmed death-ligand 1-high (≥50%), nonsquamous NSCLC, having received molecular testing within the German National Network Genomic Medicine Lung Cancer between 2017 and 2020, with Eastern Cooperative Oncology Group performance status less than or equal to 1 and pembrolizumab as first-line palliative treatment, were included into this retrospective cohort analysis. Treatment efficacy and outcome according to KRAS/TP53 status were correlated with TME composition and gene expression analysis of The Cancer Genome Atlas lung adenocarcinoma cohort., Results: Proportion of KRASmut and TP53mut was 53% (G12C 25%, non-G12C 28%) and 51%, respectively. In KRASmut patients, TP53 comutations increased response rates (G12C: 69.7% versus 46.5% [TP53mut versus wild-type (wt)], p = 0.004; non-G12C: 55.4% versus 39.5%, p = 0.03), progression-free survival (G12C: hazard ratio [HR] = 0.59, p = 0.009, non-G12C: HR = 0.7, p = 0.047), and overall survival (G12C: HR = 0.72, p = 0.16, non-G12C: HR = 0.56, p = 0.002), whereas no differences were observed in KRASwt patients. After a median follow-up of 41 months, G12C/TP53mut patients experienced the longest progression-free survival and overall survival (33.7 and 65.3 mo), which correlated with high tumor-infiltrating lymphocyte densities in the TME and up-regulation of interferon gamma target genes. Proinflammatory pathways according to TP53 status (mut versus wt) were less enhanced and not different in non-G12C and KRASwt, respectively., Conclusions: G12C/TP53 comutations identify a subset of patients with a very favorable long-term survival with immune checkpoint inhibitor monotherapy, mediated by highly active interferon gamma signaling in a proinflammatory TME., (Copyright © 2023 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
27. Mobocertinib in Patients with EGFR Exon 20 Insertion-Positive Non-Small Cell Lung Cancer (MOON): An International Real-World Safety and Efficacy Analysis.
- Author
-
Illini O, Saalfeld FC, Christopoulos P, Duruisseaux M, Vikström A, Peled N, Demedts I, Dudnik E, Eisert A, Hashemi SMS, Janzic U, Kian W, Mohorcic K, Mohammed S, Silvoniemi M, Rothschild SI, Schulz C, Wesseler C, Addeo A, Armster K, Itchins M, Ivanović M, Kauffmann-Guerrero D, Koivunen J, Kuon J, Pavlakis N, Piet B, Sebastian M, Velthaus-Rusik JL, Wannesson L, Wiesweg M, Wurm R, Albers-Leischner C, Aust DE, Janning M, Fabikan H, Herold S, Klimova A, Loges S, Sharapova Y, Schütz M, Weinlinger C, Valipour A, Overbeck TR, Griesinger F, Jakopovic M, Hochmair MJ, and Wermke M
- Subjects
- Male, Humans, Female, Aged, ErbB Receptors genetics, Exons, Carcinoma, Non-Small-Cell Lung drug therapy, Carcinoma, Non-Small-Cell Lung genetics, Lung Neoplasms drug therapy, Lung Neoplasms genetics, Aniline Compounds, Indoles, Pyrimidines
- Abstract
EGFR exon 20 (EGFR Ex20) insertion mutations in non-small cell lung cancer (NSCLC) are insensitive to traditional EGFR tyrosine kinase inhibitors (TKIs). Mobocertinib is the only approved TKI specifically designed to target EGFR Ex20. We performed an international, real-world safety and efficacy analysis on patients with EGFR Ex20-positive NSCLC enrolled in a mobocertinib early access program. We explored the mechanisms of resistance by analyzing postprogression biopsies, as well as cross-resistance to amivantamab. Data from 86 patients with a median age of 67 years and a median of two prior lines of treatment were analyzed. Treatment-related adverse events (TRAEs) occurred in 95% of patients. Grade ≥3 TRAEs were reported in 38% of patients and included diarrhea (22%) and rash (8%). In 17% of patients, therapy was permanently discontinued, and two patients died due to TRAEs. Women were seven times more likely to discontinue treatment than men. In the overall cohort, the objective response rate to mobocertinib was 34% (95% CI, 24-45). The response rate in treatment-naïve patients was 27% (95% CI, 8-58). The median progression-free and overall survival was 5 months (95% CI, 3.5-6.5) and 12 months (95% CI, 6.8-17.2), respectively. The intracranial response rate was limited (13%), and one-third of disease progression cases involved the brain. Mobocertinib also showed antitumor activity following EGFR Ex20-specific therapy and vice versa. Potential mechanisms of resistance to mobocertinib included amplifications in MET, PIK3CA, and NRAS. Mobocertinib demonstrated meaningful efficacy in a real-world setting but was associated with considerable gastrointestinal and cutaneous toxicity.
- Published
- 2024
- Full Text
- View/download PDF
28. Neuroarchitecture of the central complex in the Madeira cockroach Rhyparobia maderae: Pontine and columnar neuronal cell types.
- Author
-
Jahn S, Althaus V, Heckmann J, Janning M, Seip AK, Takahashi N, Grigoriev C, Kolano J, and Homberg U
- Subjects
- Animals, Bees, Brain, Ecosystem, Neurons, Cockroaches, Cerebellar Vermis
- Abstract
Insects have evolved remarkable abilities to navigate over short distances and during long-range seasonal migrations. The central complex (CX) is a navigation center in the insect brain that controls spatial orientation and directed locomotion. It is composed of the protocerebral bridge (PB), the upper (CBU) and lower (CBL) division of the central body, and a pair of noduli. While most of its functional organization and involvement in head-direction coding has been obtained from work on flies, bees, and locusts that largely rely on vision for navigation, little contribution has been provided by work on nocturnal species. To close this gap, we have investigated the columnar organization of the CX in the cockroach Rhyparobia maderae. Rhyparobia maderae is a highly agile nocturnal insect that relies largely but not exclusively on antennal information for navigation. A particular feature of the cockroach CX is an organization of the CBU and CBL into interleaved series of eight and nine columns. Single-cell tracer injections combined with imaging and 3D analysis revealed five systems of pontine neurons connecting columns along the vertical and horizontal axis and 18 systems of columnar neurons with topographically organized projection patterns. Among these are six types of neurons with no correspondence in other species. Many neurons send processes into the anterior lip, a brain area highly reduced in bees and unknown in flies. While sharing many features with the CX in other species, the cockroach CX shows some unique attributes that may be related to the ecological niche of this insect., (© 2023 The Authors. The Journal of Comparative Neurology published by Wiley Periodicals LLC.)
- Published
- 2023
- Full Text
- View/download PDF
29. Rationale and Design of the Phase II ANTELOPE Study of Atezolizumab, Carboplatin and nab-Paclitaxel vs. Pembrolizumab, Platinum and Pemetrexed in TTF-1 Negative, Metastatic Lung Adenocarcinoma (AIO-TRK-0122).
- Author
-
Frost N, Bleckmann A, Griesinger F, Grohé C, Janning M, Kollmeier J, Reinmuth N, Sebastian M, Thomas M, and Reck M
- Subjects
- Humans, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Carboplatin, Pemetrexed therapeutic use, Platinum therapeutic use, Retrospective Studies, Thyroid Nuclear Factor 1, Adenocarcinoma drug therapy, Adenocarcinoma of Lung drug therapy, Carcinoma, Non-Small-Cell Lung pathology, Lung Neoplasms pathology
- Abstract
Introduction: Pemetrexed-based immunochemotherapy represents an established standard of care as first line treatment for non-oncogenic driven metastatic non-small cell lung adenocarcinoma (NSCLC/ADC). However, retrospective analyses revealed better outcomes for pemetrexed-free regimens compared to pemetrexed-containing regimens in patients with thyroid transcription factor 1 (TTF-1) negative NSCLC/ADC. The multicenter, phase II, randomized, open-label ANTELOPE trial evaluates whether atezolizumab, carboplatin and nab-paclitaxel is superior to pembrolizumab, cis-/carboplatin and pemetrexed in TTF-1 negative NSCLC/ADC., Methods: Eligible participants are ≥18 years of age, with histologically or cytologically confirmed, treatment-naïve stage IV TTF-1 negative NSCLC/ADC without actionable genomic alterations or PD-L1-overexpression (TPS ≥50%) and will be randomized in a 1:1 fashion to pemetrexed-free (group A) vs. pemetrexed-based (group B) immunochemotherapy. The primary endpoint of this trial is overall survival (OS)., Results: Enrollment will start in Q2 2023 at 30 sites in Germany with a planned inclusion of 136 participants., Conclusion: ANTELOPE will provide efficacy outcomes of the current standard-of-care for the specific subset of TTF-1 negative NSCLC/ADC in a head-to-head comparison of approved immunochemotherapy regimens., (Copyright © 2023 Elsevier Inc. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
30. Detection and Monitoring of Tumor-Derived Mutations in Circulating Tumor DNA Using the UltraSEEK Lung Panel on the MassARRAY System in Metastatic Non-Small Cell Lung Cancer Patients.
- Author
-
Leest PV, Janning M, Rifaela N, Azpurua MLA, Kropidlowski J, Loges S, Lozano N, Sartori A, Irwin D, Lamy PJ, Hiltermann TJN, Groen HJM, Pantel K, Kempen LCV, Wikman H, and Schuuring E
- Subjects
- Humans, Mutation, Disease Progression, Lung, Circulating Tumor DNA genetics, Carcinoma, Non-Small-Cell Lung diagnosis, Carcinoma, Non-Small-Cell Lung genetics, Lung Neoplasms diagnosis, Lung Neoplasms genetics, Cell-Free Nucleic Acids
- Abstract
Analysis of circulating tumor DNA (ctDNA) is a potential minimally invasive molecular tool to guide treatment decision-making and disease monitoring. A suitable diagnostic-grade platform is required for the detection of tumor-specific mutations with high sensitivity in the circulating cell-free DNA (ccfDNA) of cancer patients. In this multicenter study, the ccfDNA of 72 patients treated for advanced-stage non-small cell lung cancer (NSCLC) was evaluated using the UltraSEEK
® Lung Panel on the MassARRAY® System, covering 73 hotspot mutations in EGFR , KRAS , BRAF , ERBB2 , and PIK3CA against mutation-specific droplet digital PCR (ddPCR) and routine tumor tissue NGS. Variant detection accuracy at primary diagnosis and during disease progression, and ctDNA dynamics as a marker of treatment efficacy, were analyzed. A multicenter evaluation using reference material demonstrated an overall detection rate of over 90% for variant allele frequencies (VAFs) > 0.5%, irrespective of ccfDNA input. A comparison of UltraSEEK® and ddPCR analyses revealed a 90% concordance. An 80% concordance between therapeutically targetable mutations detected in tumor tissue NGS and ccfDNA UltraSEEK® analysis at baseline was observed. Nine of 84 (11%) tumor tissue mutations were not covered by UltraSEEK® . A decrease in ctDNA levels at 4-6 weeks after treatment initiation detected with UltraSEEK® correlated with prolonged median PFS (46 vs. 6 weeks; p < 0.05) and OS (145 vs. 30 weeks; p < 0.01). Using plasma-derived ccfDNA, the UltraSEEK® Lung Panel with a mid-density set of the most common predictive markers for NSCLC is an alternative tool to detect mutations both at diagnosis and during disease progression and to monitor treatment response.- Published
- 2023
- Full Text
- View/download PDF
31. Profile of the multicenter cohort of the German Cancer Consortium's Clinical Communication Platform.
- Author
-
Maier D, Vehreschild JJ, Uhl B, Meyer S, Berger-Thürmel K, Boerries M, Braren R, Grünwald V, Hadaschik B, Palm S, Singer S, Stuschke M, Juárez D, Delpy P, Lambarki M, Hummel M, Engels C, Andreas S, Gökbuget N, Ihrig K, Burock S, Keune D, Eggert A, Keilholz U, Schulz H, Büttner D, Löck S, Krause M, Esins M, Ressing F, Schuler M, Brandts C, Brucker DP, Husmann G, Oellerich T, Metzger P, Voigt F, Illert AL, Theobald M, Kindler T, Sudhof U, Reckmann A, Schwinghammer F, Nasseh D, Weichert W, von Bergwelt-Baildon M, Bitzer M, Malek N, Öner Ö, Schulze-Osthoff K, Bartels S, Haier J, Ammann R, Schmidt AF, Guenther B, Janning M, Kasper B, Loges S, Stilgenbauer S, Kuhn P, Tausch E, Runow S, Kerscher A, Neumann M, Breu M, Lablans M, and Serve H
- Subjects
- Adolescent, Adult, Child, Child, Preschool, Female, Humans, Infant, Infant, Newborn, Male, Young Adult, Middle Aged, Aged, Aged, 80 and over, Cohort Studies, Neoplasms diagnosis, Neoplasms epidemiology, Neoplasms therapy
- Abstract
Treatment concepts in oncology are becoming increasingly personalized and diverse. Successively, changes in standards of care mandate continuous monitoring of patient pathways and clinical outcomes based on large, representative real-world data. The German Cancer Consortium's (DKTK) Clinical Communication Platform (CCP) provides such opportunity. Connecting fourteen university hospital-based cancer centers, the CCP relies on a federated IT-infrastructure sourcing data from facility-based cancer registry units and biobanks. Federated analyses resulted in a cohort of 600,915 patients, out of which 232,991 were incident since 2013 and for which a comprehensive documentation is available. Next to demographic data (i.e., age at diagnosis: 2.0% 0-20 years, 8.3% 21-40 years, 30.9% 41-60 years, 50.1% 61-80 years, 8.8% 81+ years; and gender: 45.2% female, 54.7% male, 0.1% other) and diagnoses (five most frequent tumor origins: 22,523 prostate, 18,409 breast, 15,575 lung, 13,964 skin/malignant melanoma, 9005 brain), the cohort dataset contains information about therapeutic interventions and response assessments and is connected to 287,883 liquid and tissue biosamples. Focusing on diagnoses and therapy-sequences, showcase analyses of diagnosis-specific sub-cohorts (pancreas, larynx, kidney, thyroid gland) demonstrate the analytical opportunities offered by the cohort's data. Due to its data granularity and size, the cohort is a potential catalyst for translational cancer research. It provides rapid access to comprehensive patient groups and may improve the understanding of the clinical course of various (even rare) malignancies. Therefore, the cohort may serve as a decisions-making tool for clinical trial design and contributes to the evaluation of scientific findings under real-world conditions., (© 2023. The Author(s).)
- Published
- 2023
- Full Text
- View/download PDF
32. Molecular response patterns in relapsed/refractory AML patients treated with selinexor and chemotherapy.
- Author
-
Klement P, Fiedler W, Gabdoulline R, Dallmann LK, Wienecke CP, Schiller J, Kandziora C, Teich K, Heida B, Büttner K, Brandes M, Funke C, Wichmann M, Othman B, Chromik J, Amberg S, Kebenko M, Schlipfenbacher V, Wilke AC, Modemann F, Janning M, Serve H, Bokemeyer C, Theile S, Deppermann U, Kranich AL, Ganser A, Thol F, and Heuser M
- Subjects
- Humans, Prognosis, Recurrence, Leukemia, Myeloid, Acute drug therapy, Leukemia, Myeloid, Acute genetics, Hematopoietic Stem Cell Transplantation
- Abstract
Relapse in patients with acute myeloid leukemia (AML) is common and is associated with a dismal prognosis. Treatment options are limited and the understanding of molecular response patterns is still challenging. We analyzed the clonal response patterns of 15 patients with relapsed/refractory AML treated with selinexor in a phase II trial (SAIL). DNA was analyzed at three time points and showed a decline of mutated alleles in FLT3, SF3B1, and TP53 under SAIL treatment. Overall survival (OS) was similar between patients with declining versus persisting clones. We show an interesting long-term course of a patient who relapsed after allogeneic stem cell transplantation (alloHCT) with SF3B1- and SRSF2-mutated AML and received selinexor as maintenance treatment for 4 years. Measurable residual disease (MRD) remained detectable for 2 weeks after donor lymphocyte infusion (DLI) in this patient and then remained negative under selinexor maintenance treatment. Selinexor was tolerated well and was stopped after 4 years of SAIL treatment. We present an exploratory study and identify subclonal patterns of patients treated with selinexor., (© 2022. The Author(s).)
- Published
- 2023
- Full Text
- View/download PDF
33. Targeting the EGF receptor family in non-small cell lung cancer-increased complexity and future perspectives.
- Author
-
Boch T, Köhler J, Janning M, and Loges S
- Subjects
- Humans, ErbB Receptors genetics, Mutation, Protein Kinase Inhibitors pharmacology, Protein Kinase Inhibitors therapeutic use, Carcinoma, Non-Small-Cell Lung drug therapy, Carcinoma, Non-Small-Cell Lung genetics, Lung Neoplasms drug therapy, Lung Neoplasms genetics
- Abstract
Lung cancer remains the leading cause of cancer-associated mortality worldwide, but with the emergence of oncogene targeted therapies, treatment options have tremendously improved. Owing to their biological relevance, members of the ERBB receptor family, including the EGF receptor (EGFR), HER2, HER3 and HER4, are among the best studied oncogenic drivers. Activating EGFR mutations are frequently observed in non-small cell lung cancer (NSCLC), and small molecule tyrosine kinase inhibitors (TKIs) are the established first line treatment option for patients whose tumors bear "typical/classical" EGFR mutations (exon 19 deletions, L858R point mutations). Additionally, new TKIs are rapidly evolving with better efficacy to overcome primary and secondary treatment resistance (e.g., that due to T790M or C797S resistance mutations). Some atypical EGFR mutations, such as the most frequent exon 20 insertions, exhibit relative resistance to earlier generation TKIs through steric hindrance. In this subgroup, newer TKIs, such as mobocertinib and the bi-specific antibody amivantamab have recently been approved, whereas less frequent atypical EGFR mutations remain understudied. In contrast to EGFR, HER2 has long remained a challenging target, but better structural understanding has led to the development of newer generations of TKIs. The recent FDA approval of the antibody-drug conjugate trastuzumab-deruxtecan for pretreated patients with HER2 mutant NSCLC has been an important therapeutic breakthrough. HER3 and HER4 also exert oncogenic potential, and targeted treatment approaches are being developed, particularly for HER3. Overall, strategies to inhibit the oncogenic function of ERBB receptors in NSCLC are currently evolving at an unprecedented pace; therefore, this review summarizes current treatment standards and discusses the outlook for future developments., Competing Interests: TB: received speaker honoraria from AstraZeneca and Amgen. JK: received a research grant from Eli Lilly and Company. MJ: received speaker’s honoraria and/or advisory board compensation from Roche, Boehringer Ingelheim, Amgen, AstraZeneca and Novartis. SL: received advisory board compensation, speaker honoraria and travel support from Lilly, Sanofi, BerGenBio, Novartis, Boehringer Ingelheim, BMS, Roche, AstraZeneca, MSD, Merck, Sanofi-Aventis, Janssen, Takeda, Pfizer, Amgen, Bayer, Medac and Daiichi-Sankyo, and research funding from Roche, BMS, Lilly, ADC Therapeutics and BerGenBio., (Copyright © 2022 Cancer Biology & Medicine.)
- Published
- 2022
- Full Text
- View/download PDF
34. The impact of TP53 co-mutations and immunologic microenvironment on outcome of lung cancer with EGFR exon 20 insertions.
- Author
-
Christopoulos P, Kluck K, Kirchner M, Lüders H, Roeper J, Falkenstern-Ge RF, Szewczyk M, Sticht F, Saalfeld FC, Wesseler C, Hackanson B, Dintner S, Faehling M, Kuon J, Janning M, Kauffmann-Guerrero D, Kazdal D, Kurz S, Eichhorn F, Bozorgmehr F, Shah R, Tufman A, Wermke M, Loges S, Brueckl WM, Schulz C, Misch D, Frost N, Kollmeier J, Reck M, Griesinger F, Grohé C, Hong JL, Lin HM, Budczies J, Stenzinger A, and Thomas M
- Subjects
- Brain Neoplasms genetics, Brain Neoplasms secondary, Exons, Humans, Mutation, Platinum therapeutic use, Protein Kinase Inhibitors therapeutic use, Retrospective Studies, Tumor Microenvironment genetics, Antineoplastic Agents therapeutic use, Carcinoma, Non-Small-Cell Lung drug therapy, Carcinoma, Non-Small-Cell Lung genetics, Carcinoma, Non-Small-Cell Lung pathology, ErbB Receptors genetics, Lung Neoplasms drug therapy, Lung Neoplasms genetics, Lung Neoplasms pathology, Tumor Suppressor Protein p53 genetics
- Abstract
Background: EGFR exon20 insertions (ex20ins) are targeted by novel compounds in non-small-cell lung cancer (NSCLC). However, data about outcome under conventional therapies and the influence of molecular features are scarce., Patients and Methods: We retrospectively analysed 118 patients with evaluation of radiologic response based on RECIST v1.1. TP53 status was available for 88 cases., Results: Platinum doublets and chemoimmunotherapy showed similar response rates (20-25%), disease control rates (80%) and median progression-free survival (mPFS, ≈7 months), which were longer compared to monochemotherapy (9%, 59%, 4.1 months), EGFR inhibitors (0%, 46%, 3.0) and PD-(L)1 inhibitors (0%, 30%, 2.1; p < 0.05). Overall survival (OS) was not dependent on the choice of first-line treatment, but related to more lines of systemic therapy (p < 0.05). TP53 mutations and brain metastases were associated with shorter PFS under platinum doublets and EGFR inhibitors (HR 3.3-6.1, p < 0.01), and shorter OS for patients receiving both treatments (p < 0.05). More tumour CD8
+ and less Th1 cells were associated with longer OS independent of brain and TP53 status (p < 0.01). No difference in outcome was noted according to the ex20ins site and use of pemetrexed (vs. other cytotoxics) or bevacizumab. Long-lasting responses (>1 year) occasionally occurred under EGFR inhibitors for both 'near-' and 'far-loop' variants., Conclusions: Platinum doublets and chemoimmunotherapy have the highest activity with ORR of 20-25% and mPFS of approximately 7 months, regardless of the cytotoxic partner, while PD-(L)1 inhibitors show limited efficacy. TP53 mutations, brain metastases and a lower tumour CD8/Th1-cell ratio are independently associated with shorter survival., Competing Interests: Conflict of interest statement PC: research funding from Amgen, AstraZeneca, Boehringer Ingelheim, Novartis, Roche, Takeda, and advisory board/lecture fees from AstraZeneca, Boehringer Ingelheim, Chugai, Daiichi Sankyo, Gilead, Novartis, Pfizer, Roche, Takeda. JR: lecture fees from AstraZeneca, Boehringer Ingelheim. FCS: research funding from Roche; non-financial support from Lilly; personal fees from Takeda, and Pfizer, outside the submitted work. BH: advisory board/lecture fees from AstraZeneca, Boehringer Ingelheim, BMS, MSD, Roche, Pfizer. JK: research funding from AstraZeneca and Celgene. MJ: speaker's honoraria from Roche, Boehringer, and travel grants from Daiichi Sankyo. DK: advisory boards/speakers honoraria from AstraZeneca, BMS, Boehringer Ingelheim, GSK, MSD, Novartis, Pfizer, Roche, Takeda. FE: speaker's honoraria from Roche. FB: research funding from AstraZeneca, BMS and Roche, and travel grants from BMS and MSD. RS: research funding from BMS, and speaker's honoraria from AstraZeneca and Roche. AT: research funding from BMS. MW: research funding from Roche; Personal fees from Roche, AstraZeneca, Boehringer, Kite, Novartis, Merck, BMS, Heidelberg Pharma; Non-financial support from AstraZeneca, BMS, Glenmark; outside the submitted work. SL: advisory board, speaker's honoraria and travel support from BerGenBio, Novartis, Lilly, BMS, MSD, Roche, Celgene, Takeda, AstraZeneca, Sanofi, as well as research funding from Roche, BMS, BerGenBio. WB: consulting fees from AstraZeneca, Boehringer Ingelheim, BMS, Lilly, MSD, Pfizer, Roche, Sanofi, honoraria for lectures from AstraZeneca, Boehringer Ingelheim, BMS, Lilly, MSD, Pfizer, Roche, Sanofi. Travel grants from AstraZeneca, Boehringer Ingelheim, MSD, Roche. CS: advisory board honoraria from AstraZeneca, Boehringer Ingelheim, BMS, MSD, Novartis, Roche, Pfizer, Takeda. Speaker's honoraria from AstraZeneca, Boehringer, Lilly, Roche, MSD, Takeda. DM: advisory board/lecture fees from AstraZeneca, BMS, Boehringer Ingelheim, Lilly, MSD, Novartis, Roche, Sanofi and Takeda (no personal honoraria) NF: advisory board/lecture fees from AbbVie, AstraZeneca, BMS, Boehringer Ingelheim, Pfizer, Roche, MSD, Takeda. JK: advisory board member without receiving any personal fees for Roche Pharma, Boehringer Ingelheim, BMS, MSD, Amgen, Lilly and Takeda. MR: advisory board/lecture fees from Amgen, AstraZeneca, BMS, Boehringer, Lilly, Merck, MSD, Novartis, Pfizer, Roche, Samsung. FG: grants and personal fees from AstraZeneca, Boehringer Ingelheim, BMS, Eli Lilly, MSD, Novartis, Pfizer, Roche, Takeda, as well as personal fees from AbbVie, Tesaro/GSK, Blueprint Medicines, Amgen. CG: advisory board/lecture fees from Amgen, AstraZeneca, BMS, Boehringer Ingelheim, Eli Lilly, Takeda, MSD, Novartis, Pfizer, Roche, AbbVie, Tesaro/GSK and Blueprints Medicines. AS: advisory board honoraria from BMS, AstraZeneca, ThermoFisher, Novartis, speaker's honoraria from BMS, Illumina, AstraZeneca, Novartis, ThermoFisher, MSD, Roche, and research funding from Chugai and BMS. MT: advisory board honoraria from Novartis, Eli Lilly, BMS, MSD, Roche, Celgene, Takeda, AbbVie, Boehringer Ingelheim, Pfizer, speaker's honoraria from Eli Lilly, MSD, Takeda, Pfizer, research funding from AstraZeneca, BMS, Celgene, Novartis, Roche, Takeda, and travel grants from BMS, MSD, Novartis, Boehringer. All remaining authors have declared no conflicts of interest., (Copyright © 2022 Elsevier Ltd. All rights reserved.)- Published
- 2022
- Full Text
- View/download PDF
35. Pathologic responses in oligometastatic NSCLC patients treated with neoadjuvant immune checkpoint blockade with and without chemotherapy followed by surgery.
- Author
-
Boch T, Frost N, Sommer L, Overbeck TR, Michaeli CT, Szuszies CJ, Rieckmann LM, Beumer N, Imbusch CD, Winter H, Thomas M, Roeper J, Janning M, Griesinger F, Wermke M, and Loges S
- Subjects
- Humans, Immune Checkpoint Inhibitors, Neoadjuvant Therapy, Retrospective Studies, Carcinoma, Non-Small-Cell Lung drug therapy, Lung Neoplasms drug therapy
- Abstract
Objectives: Immune checkpoint inhibitors (ICI) have significantly improved outcome of patients with advanced NSCLC and recently also showed benefit in early-stage disease. Patients with oligometastatic disease (OMD) harbor limited metastases, resectable primary tumors and derive benefit from treatment with multimodal locally ablative and systemic therapy approaches. Nothing is known about feasibility and efficacy of neoadjuvant ICI in this setting., Material and Methods: We here provide data from a multicenter retrospective study comprising 13 patients with NSCLC and OMD (≤3 distant metastases) from 5 university medical centers in Germany who have been treated with neoadjuvant ICI alone (n = 4) or in combination with chemotherapy (CT) (n = 9) prior to resection of the primary tumor. We analyzed complete (pCR) and major pathological remission (MPR) rates., Results: These data show that neoadjuvant immunotherapy applied mostly in combination with CT results in high rates of pCR and MPR (54 and 69%, respectively). Up to now, 85% of patients are free of progression with a median follow-up of 9 months (3-28 months). Single cell RNASeq analysis of tumor tissue from one patient treated with CT-ICI indicates a strong predominance of adaptive immune cell populations over a small minority of epithelial (tumor) cells., Conclusion: Neoadjuvant ICI with or without CT is a promising therapeutic concept in patients with OMD., (Copyright © 2021 Elsevier B.V. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
36. Efferocytosis fuels malignant pleural effusion through TIMP1.
- Author
-
Zhao L, Giannou AD, Xu Y, Shiri AM, Liebold I, Steglich B, Bedke T, Zhang T, Lücke J, Scognamiglio P, Kempski J, Woestemeier A, Chen J, Agalioti T, Zazara DE, Lindner D, Janning M, Hennigs JK, Jagirdar RM, Kotsiou OS, Zarogiannis SG, Kobayashi Y, Izbicki JR, Ghosh S, Rothlin CV, Bosurgi L, Huber S, and Gagliani N
- Abstract
Malignant pleural effusion (MPE) results from the capacity of several human cancers to metastasize to the pleural cavity. No effective treatments are currently available, reflecting our insufficient understanding of the basic mechanisms leading to MPE progression. Here, we found that efferocytosis through the receptor tyrosine kinases AXL and MERTK led to the production of interleukin-10 (IL-10) by four distinct pleural cavity macrophage (Mφ) subpopulations characterized by different metabolic states and cell chemotaxis properties. In turn, IL-10 acts on dendritic cells (DCs) inducing the production of tissue inhibitor of metalloproteinases 1 (TIMP1). Genetic ablation of Axl and Mertk in Mφs or IL-10 receptor in DCs or Timp1 substantially reduced MPE progression. Our results delineate an inflammatory cascade-from the clearance of apoptotic cells by Mφs, to production of IL-10, to induction of TIMP1 in DCs-that facilitates MPE progression. This inflammatory cascade offers a series of therapeutic targets for MPE., (Copyright © 2021 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. Distributed under a Creative Commons Attribution NonCommercial License 4.0 (CC BY-NC).)
- Published
- 2021
- Full Text
- View/download PDF
37. CD74 and CD44 Expression on CTCs in Cancer Patients with Brain Metastasis.
- Author
-
Loreth D, Schuette M, Zinke J, Mohme M, Piffko A, Schneegans S, Stadler J, Janning M, Loges S, Joosse SA, Lamszus K, Westphal M, Müller V, Glatzel M, Matschke J, Gebhardt C, Schneider SW, Belczacka I, Volkmer B, Greinert R, Yaspo ML, Harter PN, Pantel K, and Wikman H
- Subjects
- Antigens, Differentiation, B-Lymphocyte metabolism, Biomarkers, Tumor, Brain Neoplasms diagnosis, Breast Neoplasms pathology, Carcinoma, Non-Small-Cell Lung pathology, Cell Line, Tumor, Female, Histocompatibility Antigens Class II metabolism, Humans, Hyaluronan Receptors metabolism, Immunohistochemistry, Male, Mutation, Whole Genome Sequencing, Antigens, Differentiation, B-Lymphocyte genetics, Brain Neoplasms genetics, Brain Neoplasms secondary, Histocompatibility Antigens Class II genetics, Hyaluronan Receptors genetics, Neoplastic Cells, Circulating metabolism
- Abstract
Up to 40% of advance lung, melanoma and breast cancer patients suffer from brain metastases (BM) with increasing incidence. Here, we assessed whether circulating tumor cells (CTCs) in peripheral blood can serve as a disease surrogate, focusing on CD44 and CD74 expression as prognostic markers for BM. We show that a size-based microfluidic approach in combination with a semi-automated cell recognition system are well suited for CTC detection in BM patients and allow further characterization of tumor cells potentially derived from BM. CTCs were found in 50% (7/14) of breast cancer, 50% (9/18) of non-small cell lung cancer (NSCLC) and 36% (4/11) of melanoma patients. The next-generation sequencing (NGS) analysis of nine single CTCs from one breast cancer patient revealed three different CNV profile groups as well as a resistance causing ERS1 mutation. CD44 and CD74 were expressed on most CTCs and their expression was strongly correlated, whereas matched breast cancer BM tissues were much less frequently expressing CD44 and CD74 (negative in 46% and 54%, respectively). Thus, plasticity of CD44 and CD74 expression during trafficking of CTCs in the circulation might be the result of adaptation strategies.
- Published
- 2021
- Full Text
- View/download PDF
38. Integrative public data-mining pipeline for the validation of novel independent prognostic biomarkers for lung adenocarcinoma.
- Author
-
Ghandili S, Oqueka T, Schmitz M, Janning M, Körbelin J, Westphalen CB, P Haen S, Loges S, Bokemeyer C, Klose H, and K Hennigs J
- Subjects
- Biomarkers, Tumor genetics, Biomarkers, Tumor metabolism, Calcium-Binding Proteins genetics, Cohort Studies, Computer Simulation, Datasets as Topic, Humans, Ki-67 Antigen genetics, Ki-67 Antigen metabolism, Prognosis, RNA, Messenger metabolism, Survival Analysis, Transcriptome, Adenocarcinoma of Lung diagnosis, Calcium-Binding Proteins metabolism, Data Mining, Lung Neoplasms diagnosis
- Abstract
Aim: We aimed to develop a candidate-based integrative public data mining strategy for validation of novel prognostic markers in lung adenocarcinoma. Materials & methods: An in silico approach integrating meta-analyses of publicly available clinical information linked RNA expression, gene copy number and mutation datasets combined with independent immunohistochemistry and survival datasets. Results: After validation of pipeline integrity utilizing data from the well-characterized prognostic factor Ki-67, prognostic impact of the calcium- and integrin-binding protein, CIB1, was analyzed. CIB1 was overexpressed in lung adenocarcinoma which correlated with pathological tumor and pathological lymph node status and impaired overall/progression-free survival. In multivariate analyses, CIB1 emerged as UICC stage-independent risk factor for impaired survival. Conclusion: Our pipeline holds promise to facilitate further identification and validation of novel lung cancer-associated prognostic markers.
- Published
- 2020
- Full Text
- View/download PDF
39. Discovery of Targetable Genetic Alterations in NSCLC Patients with Different Metastatic Patterns Using a MassARRAY-Based Circulating Tumor DNA Assay.
- Author
-
Belloum Y, Janning M, Mohme M, Simon R, Kropidlowski J, Sartori A, Irwin D, Westphal M, Lamszus K, Loges S, Riethdorf S, Pantel K, and Wikman H
- Subjects
- Female, Genetic Association Studies methods, Genetic Testing, Humans, Male, Mutation, Neoplasm Metastasis, Neoplasm Staging, Prevalence, Prognosis, Biomarkers, Tumor, Carcinoma, Non-Small-Cell Lung diagnosis, Carcinoma, Non-Small-Cell Lung genetics, Circulating Tumor DNA, Genetic Variation, Liquid Biopsy methods, Lung Neoplasms diagnosis, Lung Neoplasms genetics
- Abstract
Circulating tumor DNA (ctDNA) has shown great promise as a minimally invasive liquid biopsy for personalized cancer diagnostics especially among metastatic patients. Here, we used a novel sensitive assay to detect clinically relevant mutations in ctDNA in blood plasma from metastatic non-small cell lung cancer (NSCLC) patients, including patients with a limited oligo-brain metastatic disease. We analyzed 66 plasma samples from 56 metastatic NSCLC patients for 74 hotspot mutations in five genes commonly mutated in NSCLC using a novel MassARRAY-based lung cancer panel with a turnaround time of only 3 days. Mutations in plasma DNA could be detected in 28 out of 56 patients (50.0%), with a variant allele frequency (VAF) ranging between 0.1% and 5.0%. Mutations were detected in 50.0% of patients with oligo-brain metastatic disease, although the median VAF was lower (0.4%) compared to multi-brain metastatic patients (0.9%) and patients with extra-cranial metastatic progression (1.2%). We observed an overall concordance of 86.4% ( n = 38/44) for EGFR status between plasma and tissue. The MassARRAY technology can detect clinically relevant mutations in plasma DNA from metastatic NSCLC patients including patients with limited, oligo-brain metastatic disease.
- Published
- 2020
- Full Text
- View/download PDF
40. Risk stratification of EGFR + lung cancer diagnosed with panel-based next-generation sequencing.
- Author
-
Christopoulos P, Kirchner M, Roeper J, Saalfeld F, Janning M, Bozorgmehr F, Magios N, Kazdal D, Volckmar AL, Brückner LM, Bochtler T, Kriegsmann M, Endris V, Penzel R, Kriegsmann K, Eichhorn M, Herth FJF, Heussel CP, El Shafie RA, Schneider MA, Muley T, Meister M, Faehling M, Fischer JR, Heukamp L, Schirmacher P, Bischoff H, Wermke M, Loges S, Griesinger F, Stenzinger A, and Thomas M
- Subjects
- ErbB Receptors genetics, High-Throughput Nucleotide Sequencing, Humans, Mutation, Protein Kinase Inhibitors therapeutic use, Retrospective Studies, Risk Assessment, Carcinoma, Non-Small-Cell Lung diagnosis, Carcinoma, Non-Small-Cell Lung genetics, Lung Neoplasms diagnosis, Lung Neoplasms genetics
- Abstract
Objective: Panel-based next-generation sequencing (NGS) is increasingly used for the diagnosis of EGFR-mutated non-small-cell lung cancer (NSCLC) and could improve risk assessment in combination with clinical parameters., Materials and Methods: To this end, we retrospectively analyzed the outcome of 400 tyrosine kinase inhibitor (TKI)-treated EGFR
+ NSCLC patients with validation of results in an independent cohort (n = 130)., Results: EGFR alterations other than exon 19 deletions (non-del19), TP53 co-mutations, and brain metastases at baseline showed independent associations of similar strengths with progression-free (PFS hazard ratios [HR] 2.1-2.3) and overall survival (OS HR 1.7-2.2), in combination defining patient subgroups with distinct outcome (EGFR+ NSCLC risk Score, "ENS", p < 0.001). Co-mutations beyond TP53 were rarely detected by our multigene panel (<5%) and not associated with clinical endpoints. Smoking did not affect outcome independently, but was associated with non-del19 EGFR mutations (p < 0.05) and comorbidities (p < 0.001). Laboratory parameters, like the blood lymphocyte-to-neutrophil ratio and serum LDH, correlated with the metastatic pattern (p < 0.01), but had no independent prognostic value. Reduced ECOG performance status (PS) was associated with comorbidities (p < 0.05) and shorter OS (p < 0.05), but preserved TKI efficacy. Non-adenocarcinoma histology was also associated with shorter OS (p < 0.05), but rare (2-3 %). The ECOG PS and non-adenocarcinoma histology could not be validated in our independent cohort, and did not increase the range of prognostication alongside the ENS., Conclusions: EGFR variant, TP53 status and brain metastases predict TKI efficacy and survival in EGFR+ NSCLC irrespective of other currently available parameters ("ENS"). Together, they constitute a practical and reproducible approach for risk stratification of newly diagnosed metastatic EGFR+ NSCLC., (Copyright © 2020 Elsevier B.V. All rights reserved.)- Published
- 2020
- Full Text
- View/download PDF
41. A Phase II study of selinexor plus cytarabine and idarubicin in patients with relapsed/refractory acute myeloid leukaemia.
- Author
-
Fiedler W, Chromik J, Amberg S, Kebenko M, Thol F, Schlipfenbacher V, Christine Wilke A, Modemann F, Janning M, Serve H, Ganser A, Bokemeyer C, Theile S, Deppermann U, Kranich AL, and Heuser M
- Subjects
- Adult, Aged, Aged, 80 and over, Combined Modality Therapy, Cytarabine administration & dosage, Drug Resistance, Neoplasm, Female, Follow-Up Studies, Gastrointestinal Diseases chemically induced, Hematologic Diseases chemically induced, Hematopoietic Stem Cell Transplantation adverse effects, Hematopoietic Stem Cell Transplantation mortality, Humans, Hydrazines administration & dosage, Idarubicin administration & dosage, Kaplan-Meier Estimate, Leukemia, Myeloid, Acute therapy, Male, Middle Aged, Progression-Free Survival, Recurrence, Triazoles administration & dosage, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Leukemia, Myeloid, Acute drug therapy, Salvage Therapy
- Published
- 2020
- Full Text
- View/download PDF
42. Influence of Androgens on Immunity to Self and Foreign: Effects on Immunity and Cancer.
- Author
-
Ben-Batalla I, Vargas-Delgado ME, von Amsberg G, Janning M, and Loges S
- Subjects
- Animals, Female, Humans, Male, Self Tolerance immunology, Androgens immunology, Immunologic Surveillance immunology, Neoplasms immunology, Receptors, Androgen immunology
- Abstract
It is well-known that sex hormones can directly and indirectly influence immune cell function. Different studies support a suppressive role of androgens on different components of the immune system by decreasing antibody production, T cell proliferation, NK cytotoxicity, and stimulating the production of anti-inflammatory cytokines. Androgen receptors have also been detected in many different cells of hematopoietic origin leading to direct effects of their ligands on the development and function of the immune system. The immunosuppressive properties of androgens could contribute to gender dimorphisms in autoimmune and infectious disease and thereby also hamper immune surveillance of tumors. Consistently, females generally are more prone to autoimmunity, while relatively less susceptible to infections, and have lower incidence and mortality of the majority of cancers compared to males. Some studies show that androgen deprivation therapy (ADT) can induce expansion of naïve T cells and increase T-cell responses. Emerging clinical data also reveal that ADT might enhance the efficacy of various immunotherapies including immune checkpoint blockade. In this review, we will discuss the potential role of androgens and their receptors in the immune responses in the context of different diseases. A particular focus will be on cancer, highlighting the effect of androgens on immune surveillance, tumor biology and on the efficacy of anti-cancer therapies including emerging immune therapies., (Copyright © 2020 Ben-Batalla, Vargas-Delgado, von Amsberg, Janning and Loges.)
- Published
- 2020
- Full Text
- View/download PDF
43. Multicenter Evaluation of Independent High-Throughput and RT-qPCR Technologies for the Development of Analytical Workflows for Circulating miRNA Analysis.
- Author
-
Babayan A, Neumann MHD, Herdean A, Shaffer JM, Janning M, Kobus F, Loges S, Di Pasquale F, Kubista M, Schlumpberger M, Lampignano R, Krahn T, Schlange T, Sprenger-Haussels M, Pantel K, and Kloten V
- Abstract
Background: Among emerging circulating biomarkers, miRNA has the potential to detect lung cancer and follow the course of the disease. However, miRNA analysis deserves further standardization before implementation into clinical trials or practice. Here, we performed international ring experiments to explore (pre)-analytical factors relevant to the outcome of miRNA blood tests in the context of the EU network CANCER-ID., Methods: Cell-free (cfmiRNA) and extracellular vesicle-derived miRNA (EVmiRNA) were extracted using the miRNeasy Serum/Plasma Advanced, and the ExoRNeasy Maxi kit, respectively, in a plasma cohort of 27 NSCLC patients and 20 healthy individuals. Extracted miRNA was investigated using small RNA sequencing and hybridization platforms. Validation of the identified miRNA candidates was performed using quantitative PCR., Results: We demonstrate the highest read counts in healthy individuals and NSCLC patients using QIAseq. Moreover, QIAseq showed 15.9% and 162.9% more cfmiRNA and EVmiRNA miRNA counts, respectively, in NSCLC patients compared to healthy control samples. However, a systematic comparison of selected miRNAs revealed little agreement between high-throughput platforms, thus some miRNAs are detected with one technology, but not with the other. Adding to this, 35% (9 of 26) of selected miRNAs in the cfmiRNA and 42% (11 of 26) in the EVmiRNA fraction were differentially expressed by at least one qPCR platform; about half of the miRNAs (54%) were concordant for both platforms., Conclusions: Changing of (pre)-analytical methods of miRNA analysis has a significant impact on blood test results and is therefore a major confounding factor. In addition, to confirm miRNA biomarker candidates screening studies should be followed by targeted validation using an independent platform or technology.
- Published
- 2020
- Full Text
- View/download PDF
44. Evaluation of PD-L1 expression on circulating tumor cells (CTCs) in patients with advanced urothelial carcinoma (UC).
- Author
-
Bergmann S, Coym A, Ott L, Soave A, Rink M, Janning M, Stoupiec M, Coith C, Peine S, von Amsberg G, Pantel K, and Riethdorf S
- Subjects
- B7-H1 Antigen genetics, Humans, Vimentin, Carcinoma, Transitional Cell, Neoplastic Cells, Circulating, Urinary Bladder Neoplasms
- Abstract
Immune checkpoint inhibition (ICI) of the PD-1/PD-L1 axis shows durable responses in a subset of patients with metastatic urothelial carcinoma (UC). However, PD-L1 expression in tumor biopsies does not necessarily correlate with response to PD-1/PD-L1 inhibitors. Thus, a reliable predictive biomarker is urgently needed. Here, the expression of PD-L1 on circulating tumor cells (CTCs) in blood from patients with advanced UC was analyzed. For this purpose, an assay to test PD-L1 expression on CTCs using the CellSearch® system was established using cells of five UC cell lines spiked into blood samples from healthy donors and applied to a heterogeneous cohort of UC patients. Enumeration of CTCs was performed in blood samples from 49 patients with advanced UC. PD-L1 expression in ≥1 CTC was found in 10 of 16 CTC-positive samples (63%). Both intra- and inter-patient heterogeneity regarding PD-L1 expression of CTCs were observed. Furthermore, vimentin-expressing CTCs were detected in 4 of 15 CTC-positive samples (27%), independently of PD-L1 analysis. Both CTC detection and presence of CTCs with moderate or strong PD-L1 expression correlated with worse overall survival. Analyses during disease course of three individual patients receiving ICI suggest that apart from CTC numbers also PD-L1 expression on CTCs might potentially indicate disease progression. This is the first study demonstrating the feasibility to detect CTC-PD-L1 expression in patients with advanced UC using the CellSearch® system. This assay is readily available for clinical application and could be implemented in future clinical trials to evaluate its relevance for predicting and monitoring response to ICI., (© 2020 The Author(s). Published with license by Taylor & Francis Group, LLC.)
- Published
- 2020
- Full Text
- View/download PDF
45. Pre-Analytical and Analytical Variables of Label-Independent Enrichment and Automated Detection of Circulating Tumor Cells in Cancer Patients.
- Author
-
Koch C, Joosse SA, Schneegans S, Wilken OJW, Janning M, Loreth D, Müller V, Prieske K, Banys-Paluchowski M, Horst LJ, Loges S, Peine S, Wikman H, Gorges TM, and Pantel K
- Abstract
Circulating tumor cells (CTCs) are promising tools for risk prediction and the monitoring of response to therapy in cancer patients. Within the EU/IMI CANCER-ID consortium, we validated CTC enrichment systems for future inclusion into clinical trials. Due to the known heterogeneity of markers expressed on CTCs, we tested the Parsortix
® system (ANGLE plc) which enables label-independent CTC enrichment from whole blood based on increased size and deformability of these tumor cells compared to leukocytes. We performed extensive comparisons both with spiked-in blood models (i.e., MDA-MB-468 tumor cell line cells spiked at very low concentration into blood from healthy donors) and validated the protocol on actual clinical samples from breast, lung, and gastrointestinal cancer patients to define optimal conditions for CTC enrichment. Multiple parameters including cassette gap, separation pressure, and cell fixatives were compared in parallel. Also, the compatibility of blood collection tubes with whole genome amplification of isolated tumor cells was demonstrated and we furthermore established a workflow for semi-automated CTC detection using a quantitative cell imager. The established workflow will contribute to supporting the use of size-based CTC enrichment platforms in clinical trials testing the clinical validity and utility of CTCs for personalized medicine.- Published
- 2020
- Full Text
- View/download PDF
46. Evaluation of soluble carbonic anhydrase IX as predictive marker for efficacy of bevacizumab: A biomarker analysis from the geparquinto phase III neoadjuvant breast cancer trial.
- Author
-
Janning M, Müller V, Vettorazzi E, Cubas-Cordova M, Gensch V, Ben-Batalla I, Zu Eulenburg C, Schem C, Fasching PA, Schnappauf B, Karn T, Fehm T, Just M, Kühn T, Holms F, Overkamp F, Krabisch P, Rack B, Denkert C, Untch M, Tesch H, Rezai M, Kittel K, Pantel K, Bokemeyer C, Loibl S, von Minckwitz G, and Loges S
- Subjects
- Adult, Aged, Bevacizumab administration & dosage, Biomarkers, Tumor blood, Chemotherapy, Adjuvant, Cyclophosphamide administration & dosage, Disease-Free Survival, Docetaxel administration & dosage, Epirubicin administration & dosage, Female, Humans, Middle Aged, Neoadjuvant Therapy, Young Adult, Antigens, Neoplasm blood, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Breast Neoplasms drug therapy, Breast Neoplasms enzymology, Carbonic Anhydrase IX blood
- Abstract
We analyzed the predictive potential of pretreatment soluble carbonic anhydrase IX levels (sCAIX) for the efficacy of bevacizumab in the phase III neoadjuvant GeparQuinto trial. sCAIX was determined by enzyme-linked immunosorbent assay (ELISA). Correlations between sCAIX and pathological complete response (pCR), disease-free and overall survival (DFS, OS) were assessed with logistic and Cox proportional hazard regression models using bootstrapping for robust estimates and internal validation. 1,160 HER2-negative patient sera were analyzed, of whom 577 received bevacizumab. Patients with low pretreatment sCAIX had decreased pCR rates (12.1 vs. 20.1%, p = 0.012) and poorer DFS (adjusted 5-year DFS 71.4 vs. 80.5 months, p = 0.010) compared to patients with high sCAIX when treated with neoadjuvant chemotherapy (NCT). For patients with low sCAIX, pCR rates significantly improved upon addition of bevacizumab to NCT (12.1 vs. 20.4%; p = 0.017), which was not the case in patients with high sCAIX (20.1% for NCT vs. 17.0% for NCT-B, p = 0.913). When analyzing DFS we found that bevacizumab improved 5-year DFS for patients with low sCAIX numerically but not significantly (71.4 vs. 78.5 months; log rank 0.234). In contrast, addition of bevacizumab worsened 5-year DFS for patients with high sCAIX (81 vs. 73.6 months, log-rank 0.025). By assessing sCAIX levels we identified a patient cohort in breast cancer that is potentially undertreated with NCT alone. Bevacizumab improved pCR rates in this group, suggesting sCAIX is a predictive biomarker for bevacizumab with regards to treatment response. Our data also show that bevacizumab is not beneficial in patients with high sCAIX., (© 2019 UICC.)
- Published
- 2019
- Full Text
- View/download PDF
47. Determination of PD-L1 Expression in Circulating Tumor Cells of NSCLC Patients and Correlation with Response to PD-1/PD-L1 Inhibitors.
- Author
-
Janning M, Kobus F, Babayan A, Wikman H, Velthaus JL, Bergmann S, Schatz S, Falk M, Berger LA, Böttcher LM, Päsler S, Gorges TM, O'Flaherty L, Hille C, Joosse SA, Simon R, Tiemann M, Bokemeyer C, Reck M, Riethdorf S, Pantel K, and Loges S
- Abstract
Circulating tumor cells (CTCs) hold great potential to answer key questions of how non-small cell lung cancer (NSCLC) evolves and develops resistance upon anti-PD-1/PD-L1 treatment. Currently, their clinical utility in NSCLC is compromised by a low detection rate with the established, Food and Drug Administration (FDA)-approved, EpCAM-based CellSearch
® System. We tested an epitope-independent method (ParsortixTM system) and utilized it to assess PD-L1 expression of CTCs from NSCLC patients. We prospectively collected 127 samples, 97 of which were analyzed with the epitope-independent system in comparison to the CellSearch system. CTCs were determined by immunocytochemistry as intact, nucleated, CD45- , pankeratins (K)+ cells. PD-L1 status of CTCs was evaluated from 89 samples. With the epitope-independent system, ≥1 CTC per blood sample was detected in 59 samples (61%) compared to 31 samples (32%) with the EpCAM-based system. Upon PD-L1 staining, 47% of patients harbored only PD-L1+ CTCs, 47% had PD-L1+ and PD-L1- CTCs, and only 7% displayed exclusively PD-L1- CTCs. The percentage of PD-L1+ CTCs did not correlate with the percentage of PD-L1+ in biopsies determined by immunohistochemistry ( p = 0.179). Upon disease progression, all patients showed an increase in PD-L1+ CTCs, while no change or a decrease in PD-L1+ CTCs was observed in responding patients ( n = 11; p = 0.001). Our data show a considerable heterogeneity in the PD-L1 status of CTCs from NSCLC patients. An increase of PD-L1+ CTCs holds potential to predict resistance to PD-1/PD-L1 inhibitors.- Published
- 2019
- Full Text
- View/download PDF
48. Identification of a High-Level MET Amplification in CTCs and cfTNA of an ALK-Positive NSCLC Patient Developing Evasive Resistance to Crizotinib.
- Author
-
Berger LA, Janning M, Velthaus JL, Ben-Batalla I, Schatz S, Falk M, Iglauer P, Simon R, Cao R, Forcato C, Manaresi N, Bramlett K, Buson G, Hanssen A, Tiemann M, Sauter G, Bokemeyer C, Riethdorf S, Reck M, Pantel K, Wikman H, and Loges S
- Subjects
- Antineoplastic Agents pharmacology, Carcinoma, Non-Small-Cell Lung drug therapy, Carcinoma, Non-Small-Cell Lung pathology, Cell-Free Nucleic Acids genetics, Female, Humans, Lung Neoplasms drug therapy, Lung Neoplasms pathology, Middle Aged, Neoplastic Cells, Circulating metabolism, Neoplastic Cells, Circulating pathology, Prognosis, Anaplastic Lymphoma Kinase metabolism, Carcinoma, Non-Small-Cell Lung genetics, Crizotinib pharmacology, Drug Resistance, Neoplasm genetics, Gene Amplification, Lung Neoplasms genetics, Proto-Oncogene Proteins c-met genetics
- Published
- 2018
- Full Text
- View/download PDF
49. Phase I/II study on cytarabine and idarubicin combined with escalating doses of clofarabine in newly diagnosed patients with acute myeloid leukaemia and high risk for induction failure (AMLSG 17-10 CIARA trial).
- Author
-
Krauter J, Fiedler W, Schlenk RF, Paschka P, Thol F, Lübbert M, Wattad M, Verbeek M, Könecke C, Neuhaus B, Papkalla A, Kebenko M, Janning M, Döhner K, Gaidzik VI, Becker H, Greil C, Reimer P, Götze KS, Döhner H, Ganser A, and Heuser M
- Subjects
- Adult, Aged, Antineoplastic Combined Chemotherapy Protocols adverse effects, Clofarabine administration & dosage, Clofarabine adverse effects, Cytarabine administration & dosage, Cytarabine adverse effects, Dose-Response Relationship, Drug, Female, Hematopoietic Stem Cell Transplantation, Humans, Idarubicin administration & dosage, Idarubicin adverse effects, Induction Chemotherapy methods, Male, Maximum Tolerated Dose, Middle Aged, Remission Induction, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Leukemia, Myeloid, Acute drug therapy
- Abstract
This open-label, multicentre phase I/II study determined the maximum tolerated dose (MTD), safety and efficacy of clofarabine administered with cytarabine and idarubicin in newly diagnosed acute myeloid leukaemia (AML) patients lacking favourable genetic aberrations. The MTD was 30 mg/m
2 clofarabine for patients below and above 60 years. The most frequently reported grade 3-4 non-haematological adverse events were infectious and gastrointestinal toxicities. Complete remission (CR)/CR with incomplete recovery rate was 67%. Allogeneic haematopoietic cell transplantation in first remission was feasible in a high proportion of younger AML patients and probably contributed to the favourable outcome compared to historical controls., (© 2018 British Society for Haematology and John Wiley & Sons Ltd.)- Published
- 2018
- Full Text
- View/download PDF
50. Anti-Angiogenics: Their Value in Lung Cancer Therapy.
- Author
-
Janning M and Loges S
- Subjects
- Angiogenesis Inhibitors pharmacology, Antibodies, Monoclonal pharmacology, Antibodies, Monoclonal therapeutic use, Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols pharmacology, Bevacizumab pharmacology, Bevacizumab therapeutic use, Carcinoma, Non-Small-Cell Lung blood supply, Carcinoma, Non-Small-Cell Lung pathology, Humans, Indoles pharmacology, Indoles therapeutic use, Lung Neoplasms blood supply, Lung Neoplasms pathology, Molecular Targeted Therapy methods, Neovascularization, Pathologic pathology, Randomized Controlled Trials as Topic, Receptors, Vascular Endothelial Growth Factor antagonists & inhibitors, Treatment Outcome, Tumor Microenvironment drug effects, Vascular Endothelial Growth Factor A antagonists & inhibitors, Ramucirumab, Angiogenesis Inhibitors therapeutic use, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Carcinoma, Non-Small-Cell Lung drug therapy, Lung Neoplasms drug therapy, Neovascularization, Pathologic drug therapy
- Abstract
Lung cancer is the second most common cancer and the leading cause of cancer-related deaths. Different targeted therapies and the introduction of immunotherapy have successfully improved outcome for patients with non-small lung cancer (NSCLC). Anti-angiogenic drugs are an essential component in the treatment of NSCLC patients. The vascular endothelial growth factor (VEGF)-A antibody bevacizumab is approved for first-line treatment of advanced-stage patients in combination with platinum-based chemotherapy. Ramucirumab, a VEGF receptor antibody, and nintedanib, an anti-angiogenic multi-tyrosine kinase inhibitor, are approved for second-line treatment in combination with docetaxel. This review provides a summary of pivotal trials with anti-angiogenic drugs in NSCLC in different settings. We give an overview of how to position anti-angiogenic therapy in the current treatment algorithms and highlight future directions. The identification of predictive biomarkers for patient selection could improve the success of anti-angiogenic drugs and represents an important area of research. In addition, novel therapeutic targets including endothelial metabolomic intermediates and cellular components of the tumor microenvironment could lead to the identification of innovative new targets besides the VEGF axis., (© 2018 S. Karger GmbH, Freiburg.)
- Published
- 2018
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.